CompletedNCT01959659
Healthcare Use and Burden of Persistent Schizophrenia Symptoms
About this title
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
Read the official source — NCT01959659This completed observational study examined healthcare use and the impact of persistent schizophrenia symptoms despite adequately dosed antipsychotic treatment.
Observational studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
This completed observational study examined healthcare use and the impact of persistent schizophrenia symptoms despite adequately dosed antipsychotic treatment.
Who was this study for?
The study included adults aged 18 or older with persistent schizophrenia symptoms for at least three months, adequate antipsychotic treatment, and no acute worsening in the previous three months.
What did participation involve?
The protocol used one visit for rating scales and questionnaires, alongside a retrospective medical-record review.
- Listed locations
- Epping and 106 more locationsSee all locations and recruitment
- Visits and schedule
- One data-collection visit; records covered the preceding 3–12 months, not a 12-month participation period.
- Study activities
- Rating scales and questionnaires
What should I know about this study?
Study treatment and care
This was a non-interventional study of existing care and medical records. It is listed as completed, so the protocol description is historical information.
Study information
Study start dateMay 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,431
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- Australia, France, Czechia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01959659
- Official title
Show the full official title
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
Get this study by email
Recruitment & locations
CompletedEpping, Australia · Everton Park, Australia · Brno, Czechia
95 more locations
- Brno, Jihormoravsky Kraj, Czechia
- Hradec Králové, Czechia
- Olomouc, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Praha 8 - Bohnice, Czechia
- Přerov, Czechia
- Bohars, France
- Bron, France
- Brumath, France
- Colombes, France
- Digne-les-Bains, France
- Fitz-James, France
- Hénin-Beaumont, France
- Leyme, France
- Lille, France
- Montauban, France
- Montpellier, France
- Neuilly-sur-Marne, France
- Novillars, France
- Paris, France
- Poitiers, France
- Pontarlier, France
- Provins, France
- Reims, France
- Rennes, France
- Saint-Égrève, France
- Saint-Nazaire, France
- Sens, France
- Verdun, France
- Chieti, Italy
- L’Aquila, Italy
- Aosta, Italy
- Foggia, Italy
- Roggiano Gravina, Italy
- Salerno, Italy
- Solofra, Italy
- Bologna, Italy
- Modena, Italy
- Rome, Italy
- Genoa, Italy
- Bergamo, Italy
- Brescia, Italy
- Legnago, Italy
- Monza, Italy
- Pieve di Coriano, Italy
- Varese, Italy
- Campobasso, Italy
- Novara, Italy
- Adrano, Italy
- Lido di Camaiore, Italy
- Pisa, Italy
- Siena, Italy
- Kemerovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Moscow Region, Russia
- Nizhny Novgorod, Russia
- Petrozavodsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Talagi, Russia
- Almería, Spain
- Manacor, Spain
- Barcelona, Spain
- L'Hospitalet de Llobregat, Spain
- Santander, Spain
- Torrelavega, Spain
- A Coruña, Spain
- Alcalá de Henares, Spain
- Arganda, Spain
- Madrid, Spain
- Majadahonda, Spain
- Málaga, Spain
- Pamploma, Spain
- Mos, Spain
- Vigo, Spain
- Langreo, Spain
- Dos Hermanas, Spain
- Reus, Spain
- Toledo, Spain
- Valencia, Spain
- Vitoria-Gasteiz, Spain
- Zaragoza, Spain
- Ankara, Türkiye
- Diyarbakır, Türkiye
- Gaziantep, Türkiye
- Istanbul, Türkiye
- Kocaeli, Türkiye
- Manisa, Türkiye
- Mersin, Türkiye
- Samsun, Türkiye
- Czechia
- Russia
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
